Form 4: Centessa Pharmaceuticals Director Samarth Kulkarni Granted 40,000 Stock Options

Centessa Pharmaceuticals plc Director Samarth Kulkarni has been granted 40,000 share options with an exercise price of $12.43, aligning his interests with shareholder value.

Summary

• Samarth Kulkarni, a Director of Centessa Pharmaceuticals plc (CNTA), was granted 40,000 share options.
• The options have an exercise price of $12.43 per share.
• The grant date for these options was June 20, 2025.
• The options become fully vested on the earlier of the first anniversary of the grant date or the Issuer's next annual meeting of shareholders, contingent on continued service as a director.
• The options have an expiration date of June 20, 2035.
• Following this transaction, Samarth Kulkarni beneficially owns 40,000 derivative securities (share options).

Sentiment

Score: 6

Explanation: Slightly positive, as the grant of options to a director aligns their interests with shareholders and can be seen as a sign of confidence in the company's future.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value only if the company's stock price increases.
• The acquisition of options by an insider can signal confidence in the company's future performance.

Future Outlook

The share options are subject to vesting conditions, requiring continued service as a director until the earlier of the first anniversary of the grant date or the next annual meeting of shareholders, indicating an expectation of continued tenure and alignment with future company performance.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, serving as a key component of executive and director compensation packages to incentivize long-term value creation and align leadership interests with shareholder returns.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across publicly traded companies, particularly in the biotech sector, to attract and retain talent and align interests.
• The specific number of options (40,000) and exercise price ($12.43) would typically be evaluated against peer companies of similar market capitalization and stage of development, though this document does not provide specific comparable company data.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director aims to align their interests with shareholders, potentially leading to decisions that enhance long-term stock value.
• Employees: While not directly impacted, such compensation practices can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The granted share options will vest in full on the earlier of June 20, 2026 (first anniversary of grant date) or Centessa Pharmaceuticals plc's next annual meeting of shareholders, subject to continued service.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, Stock Option, Director Compensation, Insider Transaction, SEC Form 4, Beneficial Ownership, Equity Grant